SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
DateJune 2, 2005_________________________________
BIOTECH HOLDINGS LTD. _
(Exact name of Registrant as specified in its charter)
#160 - 3751 Shell Road, Richmond, British Columbia, Canada, V6X 2W2 _
(Address of principal executive offices)
Commission file number0-29108 _
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F)
Form 20-F Yes Form 40-F No
(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
No
Biotech Holdings Ltd.
Filed in this Form 6-K
Documents index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOTECH HOLDINGS LTD.
By: /s/ Robert Rieveley
Name: Robert Rieveley
Title: Chief Executive Officer
Date: June 2, 2005
Mexican Pharmaceutical Group Looks to Sucanon for Market Share Increase
Vancouver, B.C., June 2, 2005 - Robert Rieveley, the President of Biotech Holdings Ltd. (TSX.V: BIO; OTCBB: BIOHF, "Biotech") announced today that Biotech^s Mexican distributor, Grupo Marzam, has been reported to view Sucanon as having the potential to increase their share of Mexico^s $7.8 US billion annual pharmaceutic distribution market.
"I am pleased that Marzam, with whom we signed a Sucanon distribution agreement last month, is seen as viewing Sucanon as having the potential to contribute significantly to their growth plans, as reported in the Mexican daily "Reforma", in the column of business commentator Dario Celis," Mr. Rieveley said.
Marzam, Mexico^s third largest pharmaceutical distributor, currently has over $1 Billion U.S. in sales and serves 18,000 pharmacies through 12 regional distribution centers. To read the information about Marzam and Sucanon, go to: www.biotechltd.com/pdf/dario-celis-may-26.pdf.
If you would like to be added to Biotech Holdings^ email list for future news updates or summary clinical materials, please go to: www.biotechltd.com/info.asp.
Biotech Holdings Ltd.^s head office is in Richmond, British Columbia. Biotech Holdings^ shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8 a.m. to 4 p.m. Pacific time, or by email at biotech@direct.ca. For background information and current stock quotations, visit Biotech^s website at www.biotechltd.com.
On behalf of the Board of Directors: /s/ Robert Rieveley, President and Director.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management^s best judgment as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.
